2X2 FACTORIAL DESIGN STUDY TO EVALUATE THE EFFECTS OF LANTUS< (INSULIN GLARGINE)

评估来得时<（甘精胰岛素）效果的 2X2 因子设计研究

• 批准号: 7608295
• 负责人: Stephen colgan Clement
• 金额: $ 1.56万
• 依托单位: CHILDREN'S RESEARCH INSTITUTE
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-12-01 至 2007-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7608295
• 关键词: Blood Glucose; Computer Retrieval of Information on Scientific Projects Database; Control Groups; Event; Funding; Future; Grant; Guidelines; IFNG gene; Institution; Insulin; Lantus; Non-Insulin-Dependent Diabetes Mellitus; Research; Research Design; Research Personnel; Resources; Risk; Source; United States National Institutes of Health; glargine

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The ORIGIN Study will evaluate whether people with IGT, IFG, and early type 2 diabetes who are at high risk for macrovascular events can be safely treated wih insulin glargine to near normal levels of blood glucose. It is hypothesized that this treatment will reduce their risk for future macrovascular and microvascular events compared to a control group who will be followed and treated according to normal guidelines.

该子项目是利用该技术的众多研究子项目之一 资源由 NIH/NCRR 资助的中心拨款提供。子项目和 研究者 (PI) 可能已从 NIH 的另一个来源获得主要资金， 因此可以在其他 CRISP 条目中表示。列出的机构是 对于中心来说，它不一定是研究者的机构。 ORIGIN 研究将评估大血管事件高风险的 IGT、IFG 和早期 2 型糖尿病患者是否可以安全地接受甘精胰岛素治疗，使其血糖接近正常水平。 据推测，与按照正常指南进行随访和治疗的对照组相比，这种治疗将降低他们未来发生大血管和微血管事件的风险。